Pfizer seeks approval for new Viagra use

Share this article:
Pfizer has filed applications with the FDA and European regulators for approval of its male impotence drug Viagra to treat the potentially fatal lung disorder pulmonary arterial hypertension.
The drug would be called Revatio for the new indication, not Viagra, and would be manufactured and marketed in a different dosage, color and shape than Viagra, the New York-based drug maker said.
Pulmonary arterial hypertension treatments include calcium channel blocker drugs Norvasc and Procardia XL, also manufactured by Pfizer and Biovail's Cardizem.
An approval would add to worldwide sales of Viagra, which generated $1.9 billion in revenue for 2003, according to a Bloomberg News report.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization. Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions